Phenotypes associated with this allele

• Allele Symbol: Cdkn2a^tm1.1Brn
• Allele Name: targeted mutation 1.1, Anton Berns
• Allele ID: MGI:2384165
• Summary: 10 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn	involves: 129P2/OlaHsd * FVB/N	MGI:3766055
cn2	Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Nf2^tm2Gth/Nf2^tm2Gth Trp53^tm1Brn/Trp53^tm1Brn	involves: 129P2/OlaHsd * 129S7/SvEvBrd	MGI:3850439
cn3	Cdkn2a^tm1.1Brn/Cdkn2a^+ Nf2^tm2Gth/Nf2^tm2Gth Trp53^tm1Brn/Trp53^tm1Brn	involves: 129P2/OlaHsd * 129S7/SvEvBrd	MGI:3850449
cn4	Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Trp53^tm1Brn/Trp53^tm1Brn	involves: 129P2/OlaHsd * 129S7/SvEvBrd	MGI:3850451
cn5	Braf^tm1.1Brd/Braf^+ Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Tg(Vil1-cre)997Gum/0	involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * SJL	MGI:5528298
cn6	Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Nf2^tm2Gth/Nf2^tm2Gth	involves: 129P2/OlaHsd * FVB/N	MGI:3850412
cn7	Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Nf2^tm2Gth/Nf2^tm2Gth Ptgds^tm1.1(cre)Gvn/Ptgds^+	involves: 129P2/OlaHsd * FVB/N	MGI:5051643
cx8	Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Pknox1^tm1Fbla/Pknox1^tm1Fbla Trp53^tm1Tyj/Trp53^tm1Tyj	involves: 129/Sv * 129P2/OlaHsd * 129S2/SvPas * C57BL/6	MGI:4839565
cx9	Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Pknox1^tm1Fbla/Pknox1^tm1Fbla	involves: 129/Sv * 129P2/OlaHsd * C57BL/6	MGI:4839469
cx10	Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Cdkn2b^tm2Brn/Cdkn2b^tm2Brn	involves: 129P2/OlaHsd * FVB/N	MGI:3766049

Genotype
MGI:3766055

hm1

• Allelic Composition: Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn
• Genetic Background: involves: 129P2/OlaHsd * FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

neoplasm ( J:71393 )

N • mice display no increased predisposition to developing tumors and do not exhibit any defects in cell cycle regulation

decreased incidence of tumors by chemical induction ( J:125189 )

• DMBA-induced tumors occur later and exhibit a much narrower diversity than those that develop in DMBA treated Cdkn2a^tm1.1Brn Cdkn2b^tm1Brn homozygotes

homeostasis/metabolism

decreased incidence of tumors by chemical induction ( J:125189 )

• DMBA-induced tumors occur later and exhibit a much narrower diversity than those that develop in DMBA treated Cdkn2a^tm1.1Brn Cdkn2b^tm1Brn homozygotes

Genotype
MGI:3850439

cn2

• Allelic Composition: Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn; Nf2^tm2Gth/Nf2^tm2Gth; Trp53^tm1Brn/Trp53^tm1Brn
• Genetic Background: involves: 129P2/OlaHsd * 129S7/SvEvBrd

mortality/aging

premature death ( J:132943 )

• following adenoviral cre treatment, median survival time is 80 days

neoplasm

increased tumor incidence ( J:132943 )

• following adenoviral cre treatment, 100% of mice develop highly invasive thoracic tumors (including malignant mesotheliomas, 47 of 51; rhabdomyosarcomas, 4 of 51; and schwannomas, 1 of 51)

• following adenoviral cre treatment, 75% of mice develop of aggressive malignant mesotheliomas at a shorter latency than in mice carrying other combinations of Cdkn2a^tm2Brn, Nf2^tm2Gth, and Trp53^tm1Brn alleles

increased rhabdomyosarcoma incidence ( J:132943 )

increased mesothelioma incidence ( J:132943 )

• following adenoviral cre treatment, 75% of mice develop of aggressive malignant mesotheliomas at a shorter latency than in mice carrying other combinations of Cdkn2a^tm2Brn, Nf2^tm2Gth, and Trp53^tm1Brn alleles

increased Schwannoma incidence ( J:132943 )

nervous system

increased Schwannoma incidence ( J:132943 )

muscle

increased rhabdomyosarcoma incidence ( J:132943 )

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
malignant mesothelioma		DOID:1790	OMIM:156240	J:132943

Genotype
MGI:3850449

cn3

• Allelic Composition: Cdkn2a^tm1.1Brn/Cdkn2a⁺; Nf2^tm2Gth/Nf2^tm2Gth; Trp53^tm1Brn/Trp53^tm1Brn
• Genetic Background: involves: 129P2/OlaHsd * 129S7/SvEvBrd

neoplasm

increased metastatic potential ( J:132943 )

• following adenoviral cre treatment, the parietal pleura often shows invasion with concomitant pleural effusion

increased tumor incidence ( J:132943 )

• following adenoviral cre treatment, 94% of mice develop aggressive thoracic tumors (including malignant mesotheliomas, 15 of 51; and rhabdomyosarcomas, 1 of 51) with the parietal pleura often showing invasion with concomitant pleural effusion

• following adenoviral cre treatment, 1% of mice develop aspecific tumors not induced by adeno-cre treatment

increased rhabdomyosarcoma incidence ( J:132943 )

increased mesothelioma incidence ( J:132943 )

homeostasis/metabolism

pleural effusion ( J:132943 )

• following adenoviral cre treatment, the parietal pleura often shows invasion with concomitant pleural effusion

respiratory system

pleural effusion ( J:132943 )

• following adenoviral cre treatment, the parietal pleura often shows invasion with concomitant pleural effusion

muscle

increased rhabdomyosarcoma incidence ( J:132943 )

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
malignant mesothelioma		DOID:1790	OMIM:156240	J:132943

Genotype
MGI:3850451

cn4

• Allelic Composition: Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn; Trp53^tm1Brn/Trp53^tm1Brn
• Genetic Background: involves: 129P2/OlaHsd * 129S7/SvEvBrd

neoplasm

increased mesothelioma incidence ( J:132943 )

• following adenoviral cre treatment, 2 of 13 mice develop malignant mesotheliomas-like thoracic tumors

Genotype
MGI:5528298

cn5

• Allelic Composition: Braf^tm1.1Brd/Braf⁺; Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn; Tg(Vil1-cre)997Gum/0
• Genetic Background: involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * SJL

neoplasm

increased intestinal adenoma incidence ( J:199307 )

• 1.3 fold increase in serrated adenomas relative to mice with unmutated Cdkn2a alleles (not statistically significant)

increased carcinoma incidence ( J:199307 )

• 6.4 fold increase in carcinomas relative to mice with unmutated Cdkn2a alleles

digestive/alimentary system

increased intestinal adenoma incidence ( J:199307 )

• 1.3 fold increase in serrated adenomas relative to mice with unmutated Cdkn2a alleles (not statistically significant)

Genotype
MGI:3850412

cn6

• Allelic Composition: Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn; Nf2^tm2Gth/Nf2^tm2Gth
• Genetic Background: involves: 129P2/OlaHsd * FVB/N

neoplasm

increased liver tumor incidence ( J:131179 )

• following adenoviral cre treatment, liver tumor development is increased compared to in untreated mice (on average 18% from 3%)

osseous metaplasia ( J:131179 )

• following treatment with adenoviral cre, 15% of mice exhibit osseous metaplasia compared to 2% of wild-type mice

increased meningioma incidence ( J:131179 )

• following treatment with adenoviral cre, meningioma development is increased compared to in untreated mice (on average 37% from 13%)

• meningiomas in adenoviral cre-treated mice share radiological features with human meningiomas

increased osteoma incidence ( J:131179 )

• following treatment with adenoviral cre, osteoma development is increased compared to in untreated mice (on average 78% from 57%)

nervous system

increased meningioma incidence ( J:131179 )

• following treatment with adenoviral cre, meningioma development is increased compared to in untreated mice (on average 37% from 13%)

• meningiomas in adenoviral cre-treated mice share radiological features with human meningiomas

hydrocephaly ( J:131179 )

• following adenoviral cre treatment, hydrocephalus is increased compared to in untreated mice (on average 56% from 36%)

abnormal meninges morphology ( J:131179 )

• following adenoviral cre treatment, meningothelial proliferation is increased compared to in untreated mice (on average 77% from 46%)

skeleton

increased osteoma incidence ( J:131179 )

• following treatment with adenoviral cre, osteoma development is increased compared to in untreated mice (on average 78% from 57%)

liver/biliary system

increased liver tumor incidence ( J:131179 )

• following adenoviral cre treatment, liver tumor development is increased compared to in untreated mice (on average 18% from 3%)

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
familial meningioma		DOID:4586		J:131179

Genotype
MGI:5051643

cn7

• Allelic Composition: Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn; Nf2^tm2Gth/Nf2^tm2Gth; Ptgds^{tm1.1(cre)Gvn}/Ptgds⁺
• Genetic Background: involves: 129P2/OlaHsd * FVB/N

nervous system

increased meningioma incidence ( J:173718 )

• mice develop a slightly higher number of meningiomas (not statistically significant) relative to Cdkn2a-sufficient animals

mortality/aging

mortality/aging ( J:173718 )

N • mice show similar survival/lifespan to Cdkn2a-sufficient animals

neoplasm

neoplasm ( J:173718 )

N • no pituitary tumors are observed

increased meningioma incidence ( J:173718 )

• mice develop a slightly higher number of meningiomas (not statistically significant) relative to Cdkn2a-sufficient animals

Genotype
MGI:4839565

cx8

• Allelic Composition: Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn; Pknox1^tm1Fbla/Pknox1^tm1Fbla; Trp53^tm1Tyj/Trp53^tm1Tyj
• Genetic Background: involves: 129/Sv * 129P2/OlaHsd * 129S2/SvPas * C57BL/6

mortality/aging

preweaning lethality, complete penetrance ( J:165811 )

• no mice are recovered (no time of death given)

Genotype
MGI:4839469

cx9

• Allelic Composition: Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn; Pknox1^tm1Fbla/Pknox1^tm1Fbla
• Genetic Background: involves: 129/Sv * 129P2/OlaHsd * C57BL/6

embryo

abnormal pluripotent precursor cell morphology ( J:165811 )

• mice exhibit the same reduced Oct4 expression domain as in Pknox1^tm1Fbla homozygotes

Genotype
MGI:3766049

cx10

• Allelic Composition: Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn; Cdkn2b^tm2Brn/Cdkn2b^tm2Brn
• Genetic Background: involves: 129P2/OlaHsd * FVB/N

neoplasm

neoplasm ( J:125189 )

N • untreated mice do not show any increased susceptibility to tumor formation within the first year

increased incidence of tumors by chemical induction ( J:125189 )

• treatment of newborns with dimethylbenzantrene (DMBA) induces the same tumors as observed in Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Cdkn2b^tm1Brn/Cdkn2b^tm1Brn Tg(ACTB-cre)2Mrt mice

• DMBA-induced tumors occur earlier and exhibit a much broader diversity than those that develop in DMBA treated Cdkn2a^tm1.1Brn homozygotes

increased skin tumor incidence ( J:125189 )

• treatment of newborns with dimethylbenzantrene (DMBA) induces skin tumors

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:125189 )

• treatment of newborns with dimethylbenzantrene (DMBA) induces the same tumors as observed in Cdkn2a^tm1.1Brn/Cdkn2a^tm1.1Brn Cdkn2b^tm1Brn/Cdkn2b^tm1Brn Tg(ACTB-cre)2Mrt mice

• DMBA-induced tumors occur earlier and exhibit a much broader diversity than those that develop in DMBA treated Cdkn2a^tm1.1Brn homozygotes

integument

increased skin tumor incidence ( J:125189 )

• treatment of newborns with dimethylbenzantrene (DMBA) induces skin tumors